Results for tag: "Lung Cancer Antibodies"

The lung cancer antibodies market is a distinct segment within the larger category of immune disorders drugs. This market focuses on the development and distribution of monoclonal antibodies designed to target and combat lung cancer by harnessing the body's immune system. Immune checkpoint inhibitors, a class of drugs within this domain, work by blocking proteins that prevent the immune system from attacking cancer cells. Other antibodies may be conjugated with cytotoxic agents to specifically target and destroy cancer cells. The treatment of lung cancer using immune-based strategies has expanded with the growing understanding of oncogenic drivers and tumor immunology. This field benefits from substantial investment in research and the rapid advancement of personalized medicine, resulting in tailored treatments that take into account individual genetic mutations associated with lung cancer. In the lung cancer antibodies market, several notable companies lead the charge. These include Roche (Genentech), which markets drugs such as atezolizumab, and Merck & Co., known for pembrolizumab. Additionally, Bristol-Myers Squibb contributes with nivolumab, while AstraZeneca offers durvalumab. These companies, among others, play a crucial role in the landscape of therapies for patients with lung cancer, offering advancements in care through immunotherapeutic approaches. Show Less Read more